Results 31 to 40 of about 168,585 (146)

Chemopreventive effects of Xiang Sha Liu Jun Zi Tang on paclitaxel-induced leucopenia and neuropathy in animals

open access: yesFrontiers in Pharmacology, 2023
Paclitaxel frequently induces peripheral neuropathy and myelosuppression during cancer treatment. According to the National Health Insurance Research Database of Taiwan, traditional Chinese medicine doctors widely use Xiang Sha Liu Jun Zi Tang (XSLJZT ...
Her-Shyong Shiah   +13 more
doaj   +1 more source

Glycyrrhizic Acid Prevents Paclitaxel-Induced Neuropathy via Inhibition of OATP-Mediated Neuronal Uptake

open access: yesCells, 2023
Peripheral neuropathy is a common side effect of cancer treatment with paclitaxel. The mechanisms by which paclitaxel is transported into neurons, which are essential for preventing neuropathy, are not well understood. We studied the uptake mechanisms of
Ines Klein   +8 more
doaj   +1 more source

Synthesis of Paclitaxel Loaded on Nanoparticles of Archaeosomes and Investigation of Its Anti-cancer Properties

open access: yesAsian Pacific Journal of Cancer Biology, 2017
Objective: In this study, the effect of archaeosomal paclitaxel drug on breast cancer MDA-MB231 cell lines was evaluated. Material and method: The experiments were conducted to assess the cytotoxicity of paclitaxel in free form and compare it with ...
Maral Mazloumi Tabrizi   +3 more
doaj   +1 more source

Pre-Clinical Investigation of Liquid Paclitaxel for Local Drug Delivery: A Pilot Study

open access: yesPharmaceuticals, 2020
The purpose of this pilot study was to investigate the feasibility of a perfusion catheter to deliver liquid paclitaxel into arterial segments. A clinically relevant rabbit ilio-femoral injury model was utilized to determine the impact of liquid ...
Claire V. Cawthon   +8 more
doaj   +1 more source

Combination of SAHA and Paclitaxel Induce Apoptosis of Human Cervical Cancer HeLa Cells

open access: yesZhongliu Fangzhi Yanjiu, 2018
Objective To investigate the inhibition effect of paclitaxel combined with SAHA on the proliferation of human cervical cancer HeLa cells in vitro and related mechanism.
ZHANG Lei   +5 more
doaj   +1 more source

Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study

open access: yesGynecologic Oncology Reports
The goal of this study was to assess the safety of nab-paclitaxel in patients with ovarian cancer or endometrial cancer who had an allergic reaction to paclitaxel.
Swapna Kochuveettil   +3 more
doaj   +1 more source

Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel

open access: yesNature Communications
Paclitaxel and nab-paclitaxel differ in therapeutic efficacy and modulation of the tumor immune microenvironment, yet the molecular basis remains poorly defined.
Yuqi Xing   +15 more
doaj   +1 more source

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients

open access: yesFrontiers in Pharmacology, 2018
Objective: The aim of this study was to explore the tolerance, variability, and pharmacokinetics (PK) of albumin-bound paclitaxel (QL, HR, ZDTQ) among Chinese breast cancer patients.Methods: Three randomized, open-label, two-period crossover ...
Qingmei Li   +8 more
doaj   +1 more source

Paclitaxel-Induced Endothelial Dysfunction in Living Rats Is Prevented by Nicorandil via Reduction of Oxidative Stress

open access: yesJournal of Pharmacological Sciences, 2012
Paclitaxel-eluting stents dramatically reduce rates of in-stent restenosis; however, paclitaxel is known to lead to endothelial dysfunction. Protective effects of nicorandil on paclitaxel-induced endothelial dysfunction by examining flow-mediated ...
Ken-ichi Serizawa   +8 more
doaj   +1 more source

Intravitreal Ranibizumab Had Limited Effect on Cystoid Macular Edema Due to Albumin-Bound Paclitaxel: A Case Report and Literature Review

open access: yesFrontiers in Oncology, 2021
Angiographically silent cystoid macular edema (CME) is a rare complication from nab-paclitaxel. Here we report a 45-year-old woman with breast cancer who developed CME after several months of treatment with albumin-bound paclitaxel (nab-paclitaxel).
Suna Ye   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy